ACR 2022 Tweet by Dr. Rachel Tate

Obesity in axial spondyloarthritis (axSpA) is not a minor comorbidity. Beyond the scale, there are several factors that need to be considered with obesity in axSpA.

The Janus kinase inhibitor (JAKi) class has been increasingly used in the management of axial spondyloarthritis (axSpA) over the past five years, offering effective oral alternatives to injectable biologics. But are all JAK inhibitors the same?

An editorial in Lancet Rheumatology calls for "..reframing axSpA as a systemic, autoimmune inflammatory disease with multiorgan involvement and substantial unmet need."The pathogenesis relies on not only HLA-B27, but also on environmental triggers, immune dysregulation, and gut inflammation. AxSpA…